BrightGene

BrightGene Bio-Medical Technology Co., Ltd. (Stock Code: 688166) is an international innovative pharmaceutical company that builds a full-industry-chain key process product and proprietary core drug technology platform based on clinical value. Since its establishment in 2001, BrightGene has become a globally leading pharmaceutical enterprise in the development, production, and sales of high-quality intermediates, specialty active pharmaceutical ingredients (APIs), and complex formulations by relying on multiple self-developed high-barrier technology platforms. Its marketed and pipeline products cover therapeutic areas including metabolism, oncology, respiratory, immunosuppression, antiviral, and antifungal treatments. As of the disclosure date of the Q1 2025 financial report, BGM0504 Injection (a dual GLP-1 and GIP receptor agonist) is undergoing Phase III clinical trials in China for both weight loss and Type 2 diabetes indications; the IND for BGM0504 Injection's weight loss indication has been approved in the United States, and the US bridging clinical study conducted in the U.S. has been largely completed, with the clinical summary report currently in progress. Oral BGM0504 tablets and the innovative drug BGM1812 (a long-acting Amylin analog) are in the preclinical research stage. Additionally, the company has established five major technology platforms for combination drug-device products: Blow-Fill-Seal integration, orally inhaled soft mist inhalers, dry powder inhalers, ophthalmic nebulization delivery, and intranasal-to-brain delivery. In the future, BrightGene will continue to focus on creating a new paradigm for controllable health management. Currently approved drug licenses include Entecavir Tablets, Esomeprazole Sodium Injection, Caspofungin Acetate Injection, Fondaparinux Sodium Injection, Oxiracetam Injection, Micafungin Sodium Injection, Oseltamivir Phosphate Capsules, Argatroban Injection, Oseltamivir Phosphate Dry Suspension, Voriconazole Injection, and Eribulin Mesylate Injection.